Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 698.15M P/E - EPS this Y 108.00% Ern Qtrly Grth -
Income -8.32M Forward P/E - EPS next Y 216.70% 50D Avg Chg 7.00%
Sales 376.97M PEG 223.75 EPS past 5Y -5.25% 200D Avg Chg 26.00%
Dividend N/A Price/Book 2.49 EPS next 5Y 2.00% 52W High Chg -27.00%
Recommedations 1.40 Quick Ratio 2.65 Shares Outstanding 41.89M 52W Low Chg 77.00%
Insider Own 5.52% ROA 2.07% Shares Float 34.51M Beta 1.74
Inst Own 85.91% ROE -2.90% Shares Shorted/Prior 3.06M/3.17M Price 17.08
Gross Margin 64.63% Profit Margin -2.22% Avg. Volume 168,491 Target Price 30.32
Oper. Margin 8.48% Earnings Date Oct 31 Volume 88,784 Change -0.99%
About Artivion, Inc.

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Artivion, Inc. News
11/09/24 Artivion Third Quarter 2024 Earnings: Beats Expectations
11/07/24 Artivion Reports Third Quarter 2024 Financial Results
11/05/24 Artivion to Participate in Upcoming Investor Conferences
10/24/24 Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2024 Financial Results
10/10/24 Artivion Announces Presentation of Late-Breaking Clinical Data at the 38th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting
09/26/24 Those who invested in Artivion (NYSE:AORT) a year ago are up 61%
09/02/24 Is Now An Opportune Moment To Examine Artivion, Inc. (NYSE:AORT)?
08/11/24 A Look At The Intrinsic Value Of Artivion, Inc. (NYSE:AORT)
08/08/24 Artivion Reports Second Quarter 2024 Financial Results
07/25/24 Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial Results
07/01/24 Artivion Amends Agreements with Endospan
06/23/24 Artivion's (NYSE:AORT) Returns Have Hit A Wall
05/08/24 Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue?
05/08/24 Shareholders Will Probably Hold Off On Increasing Artivion, Inc.'s (NYSE:AORT) CEO Compensation For The Time Being
05/06/24 Artivion Reports First Quarter 2024 Financial Results
04/29/24 Artivion Announces Presentation of New Clinical Data for On-X Aortic Heart Valve and AMDS at the 104th American Association for Thoracic Surgery (AATS) Annual Meeting
04/22/24 Artivion Announces Release Date and Teleconference Call Details for First Quarter 2024 Financial Results
04/19/24 Artivion's (NYSE:AORT) investors will be pleased with their notable 43% return over the last year
04/15/24 Is Artivion (AORT) Outperforming Other Medical Stocks This Year?
04/01/24 Artivion to Participate in the 23rd Annual Needham Virtual Healthcare Conference
AORT Chatroom

User Image MaverikIT Posted - 3 days ago

@IssabellaDC @net0trader $AORT $$FOUR @JaredSotken

User Image FlynancialAnalyst Posted - 1 week ago

$AORT $1.20B mc $XLV medical devices name quietly making a 3yr+ high wkly close on volume off consolidation at 10 wk SMA Short float % rolling over & trending lower long-term Pct of all funds long shares is at 2yr highs & rising 5.52% insider owned, only 326 watchers on Stocktwits TrendEdge.app/asset/AORT

User Image IN0V8 Posted - 1 week ago

$AORT Opportunity Stifel raises target price to $33 from $30

User Image J12underwood Posted - 2 weeks ago

$ELWS I told you check put $AORT constant upwards for months!

User Image J12underwood Posted - 2 weeks ago

$ELWS check out $AORT WHEN YOU CAN!!!

User Image JaredSotken Posted - 2 weeks ago

$AORT 🛸

User Image Doozio Posted - 2 weeks ago

Wen da FUTUre of 🧠⏰ is NOW all the SKWD bums $aort a fook their feelings FOUR eps gap n goes during 🧠⏰♾️

User Image Estimize Posted - 10/28/24

Wall St is expecting 94.76 revenue for $AORT Q3 [Reporting 11/07 AMC] http://www.estimize.com/intro/aort?chart=historical&metric_name=reven

User Image WeeklyTrader Posted - 10/23/24

Optimism is key for $AORT! RSI: 54.46% 50-day MA: $25.76 200-day MA: $22.81

User Image WeeklyTrader Posted - 1 month ago

Time to capitalize on this growth! Buy a CALL on $AORT at None! RSI: 55.08% 50-day MA: $25.56 200-day MA: $22.53

User Image insiderbuyingselling Posted - 1 month ago

$AORT new insider selling: 12430 shares. http://insiderbuyingselling.com/?t=AORT

User Image vjtweet Posted - 09/27/24

$AORT Closed some. Rest at break-even.

User Image vjtweet Posted - 09/24/24

$AORT bought some today. Kind of VCP formation.

User Image StockInvest_us Posted - 2 months ago

Signal alert: $AORT - Possible Runner https://stockinvest.us/l/A6amsuu7wK

User Image vjtweet Posted - 08/29/24

$AORT excellent price action. Long idea for tomorrow.

User Image insiderbuyingselling Posted - 3 months ago

$AORT new insider selling: 2383 shares. http://insiderbuyingselling.com/?t=AORT

User Image insiderbuyingselling Posted - 3 months ago

$AORT new insider selling: 9709 shares. http://insiderbuyingselling.com/?t=AORT

User Image epsguid Posted - 3 months ago

$AORT reported earnings of $0.07, consensus was $0.03 via @eWhispers #epsbeat http://eps.sh/d/aort

User Image Estimize Posted - 3 months ago

$AORT beats the Estimize EPS Consensus by 3c and misses the Estimize Revenue Consensus by $0.10M. Reports FQ2 earnings of 7c EPS and $9... http://www.estimize.com/aort/fq2-2024?utm_content=beat_or_miss&utm_medium=tweet&utm_source=stocktwits

User Image Stock_Titan Posted - 3 months ago

$AORT Artivion Reports Second Quarter 2024 Financial Results https://www.stocktitan.net/news/AORT/artivion-reports-second-quarter-2024-financial-qkkwuyrdhn0o.html

User Image Estimize Posted - 3 months ago

$AORT reports after the close, Estimize Consensus +0.01 EPS and +0.52M Revs compared to WS http://www.estimize.com/aort/fq2-2024?utm_content=prerelease&utm_medium=tweet&utm_source=stocktwits

User Image NVDAMillionaire Posted - 07/30/24

$AORT Artivion, Inc. (AORT): Poised for Continued Growth in the Aortic Health Market http://beyondspx.com/2024/07/28/artivion-inc-aort-poised-for-continued-growth-in-the-aortic-health-market/

User Image Stock_Titan Posted - 07/25/24

$AORT Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial Results https://www.stocktitan.net/news/AORT/artivion-announces-release-date-and-teleconference-call-details-for-ja9w7yejfisl.html

User Image MaverikIT Posted - 07/23/24

@net0trader @IsabellaDC @DonCorleone77 @Wigglyick @Cash4freedom @RonIsWrong @Im_not_Mr_Lebowski @CycleTrade $AORT +0.95 - 'bargain bin"

User Image MaverikIT Posted - 4 months ago

@net0trader @IsabellaDC @DonCorleone77 @RonIsWrong @Wigglyick @Cash4freedom @Im_not_Mr_Lebowski @CycleTrade $AORT +0.95

User Image MaverikIT Posted - 4 months ago

@IsabellaDC @net0trader @DonCorleone77 @RonIsWrong @Wigglyick @Cash4freedom @Im_not_Mr_Lebowski @CycleTrade $AORT

User Image Doozio Posted - 4 months ago

All da bums $aort a fook their bum 🐑 feelings. It’s 🧠⏰♾️!

User Image lg3rd1 Posted - 4 months ago

$AORT https://x.com/quiverquant/status/1811441228564582759?s=46

User Image MaverikIT Posted - 4 months ago

@net0trader @IsabellaDC @DonCorleone77 @Wigglyick @Cash4freedom @RonIsWrong @Im_not_Mr_Lebowski @CycleTrade $AORT +0.88

User Image DonCorleone77 Posted - 4 months ago

$AORT $LNSR $NPCE $LUNG $TELA Lake Street highlights five 'bargain bin' small cap healthcare ideas for 2H Lake Street analyst Frank Takkinen notes that small cap healthcare remains range bound while larger cap indices continue to make all-time highs and presents investors with five "bargain bin" ideas for the second half that have solid fundamentals, trade below the comp group averages, grow double-digits, and have novel technologies that the firm sees supporting durable growth or a strategic takeout. The firm highlighted Artivion (AORT) with a $30 price target, Lensar (LNSR) with an $8 target, NeuroPace (NPCE) with a $20 target, Pulmonx (LUNG) with a $12 target and TELA Bio (TELA) with a $14 price target, all of which are Buy-rated.

Analyst Ratings
Needham Buy Sep 27, 24
Stifel Buy Sep 13, 24
Needham Buy Aug 9, 24
Oppenheimer Outperform Aug 9, 24
Stifel Buy Aug 9, 24
Lake Street Buy Jul 2, 24
Stifel Buy May 7, 24
Needham Buy May 7, 24
Needham Buy Apr 8, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Horton Amy VP, Chief Accounting.. VP, Chief Accounting Officer Dec 15 Sell 19 14,397 273,543 124,040 12/19/23
Horton Amy VP, Chief Accounting.. VP, Chief Accounting Officer Dec 15 Option 16.3 14,397 234,671 138,437 12/19/23
Horton Amy VP, Chief Accounting.. VP, Chief Accounting Officer Nov 27 Sell 17.34 2,101 36,431 105,599 11/29/23
GREEN ANDREW M VP Regulatory VP Regulatory Feb 23 Sell 12.94 1,747 22,606 24,102 03/01/23
Mackin James P President & CEO President & CEO Feb 23 Sell 12.94 22,630 292,832 540,052 03/01/23
Maier Dennis B SVP, Operations SVP, Operations Feb 23 Sell 12.94 2,330 30,150 48,436 03/01/23
Stanton Marshall S. SVP, Clinical & MD A.. SVP, Clinical & MD Affair Feb 23 Sell 12.94 2,337 30,241 49,321 03/01/23
Getz Matthew A VP, Human Resources VP, Human Resources Feb 23 Sell 12.94 1,600 20,704 35,128 03/01/23
Horton Amy VP, Chief Accounting.. VP, Chief Accounting Officer Feb 17 Sell 14.1 18,000 253,800 102,663 02/21/23
Horton Amy VP, Chief Accounting.. VP, Chief Accounting Officer Feb 17 Option 10.24 20,713 212,101 105,663 02/21/23
Davis John E Senior VP, Global Sa.. Senior VP, Global Sales Feb 13 Option 10.24 8,745 89,549 120,017 02/15/23
Horton Amy VP, Chief Accounting.. VP, Chief Accounting Officer Dec 14 Sell 13.57 3,226 43,777 101,950 12/16/22
Maney Rochelle L. VP, Quality VP, Quality Aug 16 Sell 22.959 7,161 164,409 12,325 08/18/22
Maier Dennis B SVP, Operations SVP, Operations Aug 09 Sell 21.62 5,762 124,574 22,807 08/10/22
Mackin James P President & CEO President & CEO Feb 09 Option 11 21,277 234,047 314,817 02/11/22
Mackin James P President & CEO President & CEO Feb 09 Sell 18 21,277 382,986 304,178 02/11/22
Mackin James P President & CEO President & CEO Feb 08 Option 11 10,638 117,018 314,816 02/10/22
Mackin James P President & CEO President & CEO Feb 08 Sell 17.75 10,638 188,824 304,178 02/10/22
SEMEDO ANTHONY B. Director Director Nov 29 Buy 17.36 15,000 260,400 19,992 11/30/21
Davis John E Senior VP, Global Sa.. Senior VP, Global Sales May 27 Option 26.24 5,402 141,748 84,638 05/27/21
Davis John E Senior VP, Global Sa.. Senior VP, Global Sales May 27 Sell 29.67 12,739 377,966 71,899 05/27/21
Maier Dennis B Vice President, Oper.. Vice President, Operations Feb 19 Option 21.55 6,630 142,876 23,211 02/19/21
Maier Dennis B Vice President, Oper.. Vice President, Operations Feb 19 Sell 24.69 7,197 177,694 16,014 02/19/21
Capps Scott B VP, Clinical Researc.. VP, Clinical Research Dec 16 Option 9.97 10,000 99,700 157,006 12/16/20
Capps Scott B VP, Clinical Researc.. VP, Clinical Research Dec 16 Sell 21.34 8,366 178,530 148,640 12/16/20
Horton Amy VP, Chief Accounting.. VP, Chief Accounting Officer Dec 16 Option 9.97 6,666 66,460 99,642 12/16/20
Horton Amy VP, Chief Accounting.. VP, Chief Accounting Officer Dec 02 Option 9.97 6,666 66,460 99,642 12/02/20
Horton Amy VP, Chief Accounting.. VP, Chief Accounting Officer Dec 02 Sell 20.78 6,666 138,519 92,976 12/02/20